Eur Arch Otorhinolaryngol:miR-181a和miR-155的减少与Treg细胞数的减少和功能有关

2019-02-17 AlexYang MedSci原创

之前的研究表明调节细胞(Tregs)参与了过敏性气道炎症过程。最近,有研究人员评估了miRNA在AR儿童中的表达并探索了与Tregs和AR严重度的相关性。研究包括了25名AR儿童和20名健康的儿童作为对照。研究人员利用流式细胞术和没脸免疫反应对Treg细胞的比例和IL-10和TGF-β的表达进行了检测名,并进行了microRNA芯片分析了差异表达分析。研究发现,患有AR的儿童的Tregs比例和IL

之前的研究表明调节细胞(Tregs)参与了过敏性气道炎症过程。最近,有研究人员评估了miRNA在AR儿童中的表达并探索了与Tregs和AR严重度的相关性。

研究包括了25名AR儿童和20名健康的儿童作为对照。研究人员利用流式细胞术和没脸免疫反应对Treg细胞的比例和IL-10和TGF-β的表达进行了检测名,并进行了microRNA芯片分析了差异表达分析。研究发现,患有AR的儿童的Tregs比例和IL-10和TGF-β的表达水平与对照相比更低。研究还发现AR儿童的Tregs中的miR-155和miR-181a水平显著更低。更多的是,细胞内miR-155和miR-181a水平与Tregs比例和IL-10和TGF-β的表达呈现正相关关系。相似地,总鼻严重度评分(TNSS)与miR-155和miR-181a水平呈现负相关关系。

最后,研究人员指出,在AR儿童中,Treg来源的miR-155和miR-181a水平减少与Tregs数目的减少和功能相关。另外,细胞内miR-155和miR-181a水平也许可以作为儿童AR严重度的一个预示因子。

原始出处:


本文系梅斯医学(MedSci)原创编译整理,转载需授权!

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1930687, encodeId=d8f9193068e87, content=<a href='/topic/show?id=22f61180211' target=_blank style='color:#2F92EE;'>#miR#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11802, encryptionId=22f61180211, topicName=miR)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a27288, createdName=smallant2002, createdTime=Fri Sep 13 02:01:00 CST 2019, time=2019-09-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1685790, encodeId=7c391685e9091, content=<a href='/topic/show?id=7a7a11835f2' target=_blank style='color:#2F92EE;'>#miR-155#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11835, encryptionId=7a7a11835f2, topicName=miR-155)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=240328265853, createdName=124984e7m92暂无昵称, createdTime=Wed May 15 09:01:00 CST 2019, time=2019-05-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1343522, encodeId=82871343522a4, content=<a href='/topic/show?id=7dd51e788b8' target=_blank style='color:#2F92EE;'>#Treg细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17788, encryptionId=7dd51e788b8, topicName=Treg细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b3ad2500191, createdName=12498dd9m11暂无昵称, createdTime=Tue Feb 19 13:01:00 CST 2019, time=2019-02-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1477198, encodeId=25b914e7198dc, content=<a href='/topic/show?id=81f91e786ce' target=_blank style='color:#2F92EE;'>#Treg#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17786, encryptionId=81f91e786ce, topicName=Treg)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=96827361646, createdName=12498484m48(暂无昵称), createdTime=Tue Feb 19 13:01:00 CST 2019, time=2019-02-19, status=1, ipAttribution=)]
    2019-09-13 smallant2002
  2. [GetPortalCommentsPageByObjectIdResponse(id=1930687, encodeId=d8f9193068e87, content=<a href='/topic/show?id=22f61180211' target=_blank style='color:#2F92EE;'>#miR#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11802, encryptionId=22f61180211, topicName=miR)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a27288, createdName=smallant2002, createdTime=Fri Sep 13 02:01:00 CST 2019, time=2019-09-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1685790, encodeId=7c391685e9091, content=<a href='/topic/show?id=7a7a11835f2' target=_blank style='color:#2F92EE;'>#miR-155#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11835, encryptionId=7a7a11835f2, topicName=miR-155)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=240328265853, createdName=124984e7m92暂无昵称, createdTime=Wed May 15 09:01:00 CST 2019, time=2019-05-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1343522, encodeId=82871343522a4, content=<a href='/topic/show?id=7dd51e788b8' target=_blank style='color:#2F92EE;'>#Treg细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17788, encryptionId=7dd51e788b8, topicName=Treg细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b3ad2500191, createdName=12498dd9m11暂无昵称, createdTime=Tue Feb 19 13:01:00 CST 2019, time=2019-02-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1477198, encodeId=25b914e7198dc, content=<a href='/topic/show?id=81f91e786ce' target=_blank style='color:#2F92EE;'>#Treg#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17786, encryptionId=81f91e786ce, topicName=Treg)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=96827361646, createdName=12498484m48(暂无昵称), createdTime=Tue Feb 19 13:01:00 CST 2019, time=2019-02-19, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1930687, encodeId=d8f9193068e87, content=<a href='/topic/show?id=22f61180211' target=_blank style='color:#2F92EE;'>#miR#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11802, encryptionId=22f61180211, topicName=miR)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a27288, createdName=smallant2002, createdTime=Fri Sep 13 02:01:00 CST 2019, time=2019-09-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1685790, encodeId=7c391685e9091, content=<a href='/topic/show?id=7a7a11835f2' target=_blank style='color:#2F92EE;'>#miR-155#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11835, encryptionId=7a7a11835f2, topicName=miR-155)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=240328265853, createdName=124984e7m92暂无昵称, createdTime=Wed May 15 09:01:00 CST 2019, time=2019-05-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1343522, encodeId=82871343522a4, content=<a href='/topic/show?id=7dd51e788b8' target=_blank style='color:#2F92EE;'>#Treg细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17788, encryptionId=7dd51e788b8, topicName=Treg细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b3ad2500191, createdName=12498dd9m11暂无昵称, createdTime=Tue Feb 19 13:01:00 CST 2019, time=2019-02-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1477198, encodeId=25b914e7198dc, content=<a href='/topic/show?id=81f91e786ce' target=_blank style='color:#2F92EE;'>#Treg#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17786, encryptionId=81f91e786ce, topicName=Treg)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=96827361646, createdName=12498484m48(暂无昵称), createdTime=Tue Feb 19 13:01:00 CST 2019, time=2019-02-19, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1930687, encodeId=d8f9193068e87, content=<a href='/topic/show?id=22f61180211' target=_blank style='color:#2F92EE;'>#miR#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11802, encryptionId=22f61180211, topicName=miR)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a27288, createdName=smallant2002, createdTime=Fri Sep 13 02:01:00 CST 2019, time=2019-09-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1685790, encodeId=7c391685e9091, content=<a href='/topic/show?id=7a7a11835f2' target=_blank style='color:#2F92EE;'>#miR-155#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11835, encryptionId=7a7a11835f2, topicName=miR-155)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=240328265853, createdName=124984e7m92暂无昵称, createdTime=Wed May 15 09:01:00 CST 2019, time=2019-05-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1343522, encodeId=82871343522a4, content=<a href='/topic/show?id=7dd51e788b8' target=_blank style='color:#2F92EE;'>#Treg细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17788, encryptionId=7dd51e788b8, topicName=Treg细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b3ad2500191, createdName=12498dd9m11暂无昵称, createdTime=Tue Feb 19 13:01:00 CST 2019, time=2019-02-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1477198, encodeId=25b914e7198dc, content=<a href='/topic/show?id=81f91e786ce' target=_blank style='color:#2F92EE;'>#Treg#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17786, encryptionId=81f91e786ce, topicName=Treg)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=96827361646, createdName=12498484m48(暂无昵称), createdTime=Tue Feb 19 13:01:00 CST 2019, time=2019-02-19, status=1, ipAttribution=)]

相关资讯

Int Forum Allergy Rhinol:MP-AzeFlu能够提供快速有效的过敏性鼻炎控制

过敏性鼻炎(AR)控制在欧盟国家比较紧迫,并且过敏性鼻炎和对哮喘的影响(ARIA)通过视觉模拟评分(VAS)已经作为AR控制的新角度。最近,有研究人员利用VAS评估了真实生活中的MP-AzeFlu的临床实践效果。研究是一个多中心、前瞻性和非介入的研究,包括了170名患者(均不小于12岁)。他们具有ARIA定义的中度到重度AR,并指定用MP-AzeFlu治疗。研究发现,MP-AzeFlu能够减少VA

盘点:鼻炎与治疗研究盘点

【1】Int Arch Allergy Immunol:鼻腔内给药IL-27能够减轻鼻过敏性响应和症状https://www.ncbi.nlm.nih.gov/pubmed/30428479白介素(IL-27)是Th1响应的一个抑制子,并能够抑制炎症响应。在一个哮喘小鼠模型中,IL-27给药能够减少气管肺泡灌洗和气道高反应中的嗜酸性粒细胞数目。然而,是否IL-27给药能够抑制过敏性疾病和过敏性

Int Immunopharmacol:IL-37能够通过STAT6/STAT3减弱过敏性鼻炎中的过敏过程

过敏性鼻炎(AR)是一种常见的上呼吸道过敏性疾病,并且是通过过敏原激活2型免疫响应引起的。CD4+T细胞亚群的不平衡是AR的必要免疫特性,且主要是通过优势辅助性T2细胞来鉴定的。最近的研究表明了抗炎症因子白介素-37(IL-37)参与了AR的免疫调控。然而,IL-37对AR的作用机制仍旧不清楚。最近,有研究人员评估了IL-37在AR中的保护性作用,并且进一步探索了可能的机制。研究人员利用卵清蛋白(

盘点:鼻炎研究盘点

鼻炎即鼻腔炎性疾病,是病毒、细菌、变应原、各种理化因子以及某些全身性疾病引起的鼻腔黏膜的炎症。鼻炎的主要病理改变是鼻腔黏膜充血、肿胀、渗出、增生、萎缩或坏死等。梅斯医学小编整理了近期过敏性鼻炎的研究进展,与大家一起分享学习!【1】Asian Pac J Allergy Immunol:中国过敏性鼻炎与哮喘并发流行度分析https://www.ncbi.nlm.nih.gov/pubmed/30

Allergy Asthma Immunol Res:1, 25-二羟维生素D3鼻内治疗能够减轻过敏性鼻炎症状

维生素D是一种强有力的免疫调控因子。然而,在过敏性鼻炎中的角色仍旧不清楚。最近,有研究人员在过敏性鼻炎小鼠中评估了鼻内使用维生素D的抗过敏效果情况。研究人员将BALB/c小鼠在鼻内进行OVA鼻内挑战之前利用卵清蛋白(OVA)和明矾进行敏感化。之后,研究人员对其进行1, 25-二羟维生素D3给药或者溶剂给药。研究发现在治疗组,过敏性症状评分、嗜酸性粒细胞浸润和鼻组织中的IL-4和IL-13的mRNA

Rhinology:局部过敏性鼻炎的患病率和特征分析

局部过敏性鼻炎(LAR)在一些患者中发现具有典型的症状,但是那些对气源性致敏原具有阴性皮刺试验和阴性lgE的患者却表现出了对一定过敏原阳性鼻腔激发试验结果。到目前为止,对LAR的患病率和临床特征仍旧了解很少。最近,有研究人员确定了具有慢性鼻炎LAR患者的流行度和特征情况。研究包括了680名年龄不小于5岁的患者,分布于波兰的17个地点。研究总共调查了621名患者。LAR在109(17.6%)名患者中